Literature DB >> 8075587

Acute lymphoblastic leukemia (ALL): detection of minimal residual disease (MRD) at flow cytometry.

A Orfao1, J Ciudad, M C Lopez-Berges, A Lopez, B Vidriales, M D Caballero, B Valverde, M Gonzalez, J F San Miguel.   

Abstract

In the present study the usefulness of a method combining multiple staining direct immunofluorescence technique together with flow cytometry in order to predict relapse in ALL is analyzed in a group of 47 patients (11 T-ALL and 36 B-ALL). Results show that this method can be applied to at least two-thirds of all ALL patients being specially useful for the T-ALL cases (100% vs 56%) as this corresponding to the incidence of "aberrant" phenotypes. The detection of an increase in the percentage of bone marrow cells displaying "aberrant" phenotypes in two consecutive samples from the same patient is of great help on predicting relapse (sensitivity of 92% and specificity of 75%).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8075587     DOI: 10.3109/10428199409052682

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

1.  Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples: identification and enumeration.

Authors:  A Orfao; L Escribano; J Villarrubia; J L Velasco; C Cerveró; J Ciudad; J L Navarro; J F San Miguel
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

Review 2.  Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy.

Authors:  Zhiyu Liu; Yang Li; Ce Shi
Journal:  Int J Hematol       Date:  2021-01-27       Impact factor: 2.490

3.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Authors:  Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta
Journal:  Blood       Date:  2008-04-03       Impact factor: 22.113

4.  Characterization of aberrant phenotypes in acute myeloblastic leukemia.

Authors:  A Macedo; A Orfão; M B Vidriales; M C López-Berges; B Valverde; M González; M D Caballero; F Ramos; M Martínez; J Fernández-Calvo
Journal:  Ann Hematol       Date:  1995-04       Impact factor: 3.673

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.